Advertisement

Pharmacy

Home Pharmacy
Most serious adverse events in nursing homes are caused by medication errors

Causes of Serious Adverse Events in Nursing Homes Identified

Most serious adverse events caused by medication errors, falls, delayed or inappropriate intervention
The U.S. Food and Drug Administration has approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.

FDA Approves New Drug to Treat Plaque Psoriasis

Cosentyx hinders protein that spurs skin inflammation

HPV Vaccination Rates Increased After ACIP Update for Adults Aged 27 to 45

Immediate increase seen in vaccine administration rate in women; increased slope seen over time postupdate

Pandemic Increased Americans’ Concerns About Obesity

Greatest increases in concern seen among Black and Hispanic adults

The maker of Zolgensma (onasemnogene abeparvovec-xioi) gave manipulated data to the U.S. Food and Drug Administration when it approved the drug

FDA: Approval of Zolgensma Was Based on Manipulated Data

Despite inaccurate data, FDA says it is 'confident that Zolgensma should remain on the market'

Opioid Rx Down for Chronic Noncancer Pain, Cancer Pain in U.S. Adults

Declines in opioid prescribing outpacing increases in receipt of nonopioid therapies

Among cancer survivors

Factors Predict Adverse Opioid-Related Outcomes in Cancer Survivors

Demographic, cancer, and treatment factors can predict outcomes with high level of discrimination
Lower- and higher-dose elagolix are beneficial for women with endometriosis

Lower-, Higher-Dose Elagolix Beneficial for Endometriosis

Higher percentage of women have clinical response for dysmenorrhea, non-menstrual pelvic pain
Oral semaglutide is associated with better glycemic control than placebo among type 2 diabetes patients with insufficient glycemic control

Glycemic Control Up With Oral Semaglutide in Type 2 Diabetes

Phase 3 studies next to assess longer-term/clinical outcomes, safety

Adults With IBD Show Antibody Response to mRNA COVID-19 Vaccine

After mRNA COVID-19 vaccination, 99 percent of patients with IBD had detectable antibodies regardless of immunocompromising therapies